Literature DB >> 6869479

Ocular toxicity of fluorouracil after vitrectomy.

W H Stern, C J Guerin, P A Erickson, G P Lewis, D H Anderson, S K Fisher.   

Abstract

The retinal and corneal toxicity of fluorouracil in the rabbit eye after lensectomy and vitrectomy depended on both the dosage and the frequency of intraocular injection and was reversible at certain dosages. All eyes in Group 1 (1.25 mg of fluorouracil every 12 hours for four days and then every 24 hours for three days) had opaque corneas by three days; these did not clear for four weeks. Histologic studies showed loss of photoreceptor outer segments and loss of ribosomes in all the retinal cells examined. The electroretinographic b-wave decreased to 0% of the baseline value (no b-wave), and did not recover after three weeks. In Group 2 eyes (1.25 mg of fluorouracil every 24 hours for seven days), corneal opacification increased to a maximum after two weeks and gradually decreased by four weeks. The electroretinographic b-wave diminished to 9.6% of the baseline value at two weeks but later recovered to 62.5% of the baseline value at three weeks. Histologic studies showed loss of photoreceptor outer segments and ribosomes at nine days; both returned to near normal after five weeks. Clinical, electrophysiologic, and histologic studies showed no toxicity in Group 3 eyes (0.5 mg of fluorouracil every 24 hours for seven days). This dosage of fluorouracil exerts a significant antiproliferative effect on injected retinal pigment epithelial cells and is well tolerated by the rabbit eye.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6869479     DOI: 10.1016/0002-9394(83)90453-1

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  18 in total

1.  Intravitreal crystalline drug delivery for intraocular proliferation diseases.

Authors:  Lingyun Cheng; Karl Hostetler; Nadya Valiaeva; Ajay Tammewar; William R Freeman; James Beadle; Dirk-Uwe Bartsch; Kathy Aldern; Iryna Falkenstein
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-08-20       Impact factor: 4.799

2.  The use of a liposome-encapsulated 5-fluoroorotate for glaucoma surgery: I. Animal studies.

Authors:  J A Alvarado
Journal:  Trans Am Ophthalmol Soc       Date:  1989

3.  Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo.

Authors:  Haihua Zheng; Zhimin Wang; Peijuan Wang; Yaqin Liu; Zhaoxin Jiang; Qianying Gao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-11-27       Impact factor: 3.117

Review 4.  Proliferative vitreoretinopathy: pathobiology, surgical management, and adjunctive treatment.

Authors:  D G Charteris
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

5.  Effects on the visual system might contribute to some of the cognitive deficits of cancer chemotherapy-induced 'chemo-fog'.

Authors:  R B Raffa; R J Tallarida
Journal:  J Clin Pharm Ther       Date:  2010-06       Impact factor: 2.512

6.  Intravitreal liposome-encapsulated drugs: a preliminary human report.

Authors:  G A Peyman; H C Charles; K R Liu; B Khoobehi; M Niesman
Journal:  Int Ophthalmol       Date:  1988       Impact factor: 2.031

7.  Growth inhibition of human Tenon's capsule fibroblasts and rabbit dermal fibroblasts with non-carcinogenic N-alkylated anthracyclines.

Authors:  U H Steinhorst; E P Chen; S F Freedman; R Machemer; D L Hatchell
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1994-06       Impact factor: 3.117

8.  Effects of selected repeated intravitreal chemotherapeutic agents.

Authors:  J Vernot; G A Peyman; R Gailitis; R Fiscella; M Woodhouse; D Weinberg
Journal:  Int Ophthalmol       Date:  1985-11       Impact factor: 2.031

9.  Experimental posterior perforating ocular injury: a controlled study of the gross effects of localised gamma irradiation.

Authors:  U Chakravarthy; C J Maguire; D B Archer
Journal:  Br J Ophthalmol       Date:  1986-08       Impact factor: 4.638

10.  Topical application of 5-fluorouracil in premalignant lesions of cornea, conjunctiva and eyelid.

Authors:  R J de Keizer; D de Wolff-Rouendaal; J L van Delft
Journal:  Doc Ophthalmol       Date:  1986-12-30       Impact factor: 2.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.